Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer identifier:
NCT04674306 (

Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.

Study Contact Information:

Contact: George T Budd, MD      
[email protected]

About the Study

Researchers are studying the affects of this breast cancer vaccine on the immune system in the following groups:

This listing is for people who have never been diagnosed with breast cancer. If you have been diagnosed with triple-negative breast  cancer and are interested in joining the treatment portion of the study, see our study listing here

What the Study Involves 

All participants will receive the vaccinations every 2 weeks for a total of 3 doses. 

Study Location

Cleveland, Ohio 
Cleveland Clinic Case Comprehensive Cancer Center
Contact: George T Budd, MD      
[email protected]


This Study is Open To:

Prevention Group:

For the full listing visit the website

This Study is Not Open To:

Prevention Group: People with the following are not eligible to participate:

For the full listing visit the website


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.